Oaktree Acquisition Corp. II
OACB-UN
New York Stock Exchange9.65
USD
+0.15
- -
CIK
0001820931
Return %
Stock
S&P500
1Y
- -
18.21
3Y
- -
64.38
5Y
- -
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 333 South Grand Avenue Los Angeles CA United States of America 90071
- IPO Date
- Sep 17, 2020
- CIK
- 0001820931
- Website
- oaktreeacquisitioncorp.com
- Similar Companies
- Business
- Oaktree Acquisition Corp. II is a special purpose acquisition company (SPAC) incorporated in 2020 and headquartered in the Cayman Islands, focused on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Sponsored by an affiliate of Oaktree Capital Management, L.P., a global alternative investment management firm, Oaktree Acquisition Corp. II primarily serves to facilitate the public entry of target companies through a business combination. It raised approximately $225 million in its initial public offering in 2020. The company completed a significant business combination by merging with Alvotech Holdings, a global biopharmaceutical company specializing in the development and manufacture of biosimilar medicines. This merger, expected to close in mid-2022, enabled Alvotech to go public and receive gross proceeds exceeding $450 million, including $250 million from Oaktree Acquisition's trust account along with additional equity commitments and private placements from major investors. Alvotech's biosimilar platform focuses on developing therapeutic equivalents to biologic medicines targeting autoimmune disorders, eye disorders, osteoporosis, and cancer, leveraging a vertically integrated approach with in-house development, manufacturing, and regulatory capabilities. Following the merger, the combined companies' securities are expected to be listed on Nasdaq under the ticker symbol "ALVO." This transaction marked an operational shift for Oaktree Acquisition Corp. II from a blank check SPAC to a publicly traded biopharmaceutical company, broadening its business scope into the healthcare and biotechnology sector. The merger also aligns with Oaktree Capital Management's strategic intent to partner with high-growth companies delivering impactful solutions in their industries, with Alvotech exemplifying such a fit through its comprehensive biosimilar portfolio and global distribution partnerships. Prior to the business combination, Oaktree Acquisition Corp. II primarily operated within the diversified financials sector as an asset management-related SPAC. In summary, Oaktree Acquisition Corp. II specializes in identifying and facilitating business combinations, with its latest major change being the transformative merger with Alvotech, a vertically integrated biosimilar drug developer and manufacturer, significantly expanding its product and service offerings into biotechnology with a global market presence. The company is affiliated with Oaktree Capital Management and operates in global capital markets with a focus on healthcare innovation through SPAC-facilitated public listings.